Related by context. All words. (Click for frequent words.) 70 pCR 70 neoadjuvant chemotherapy 69 pegylated liposomal doxorubicin 69 CR nPR 69 chemoradiotherapy 69 adjuvant radiotherapy 69 Doxil ® 68 androgen suppression 68 neoadjuvant 67 ABVD 67 recurrent GBM 67 relapsed MM 67 cytoreduction 67 Flu Cy 67 histologically confirmed 67 tamoxifen therapy 67 neoadjuvant treatment 67 low dose cytarabine 67 XELOX 67 goserelin 67 postoperative chemotherapy 67 preoperative chemotherapy 67 estramustine 67 debulking surgery 67 chemoradiation 66 Adjuvant chemotherapy 66 partial remissions 66 5-FU/LV 66 operable breast cancer 66 Xelox 66 oblimersen 66 adjuvant cisplatin 66 APTIVUS r 66 androgen deprivation 66 clinically localized prostate 65 docetaxel chemotherapy 65 heavily pretreated patients 65 ribavirin RBV 65 TroVax ® 65 clodronate 65 biochemical relapse 65 stage IIIb IV 65 MGd 65 doxorubicin cyclophosphamide 65 adjuvant therapy 65 PegIFN RBV 65 paricalcitol 65 liver transplant recipients 65 flutamide 65 antiangiogenic therapy 65 underwent resection 65 complete cytogenetic response 65 undetectable HBV DNA 65 receiving VICTRELIS 65 chemoradiation therapy 65 liver metastasis 65 gemcitabine Gemzar 65 anastrozole 65 LHRH receptor positive 65 standard chemotherapy regimen 65 mutated KRAS 65 doxorubicin docetaxel 65 HBeAg seroconversion 65 nadolol 65 aromatase inhibitor therapy 65 locoregional recurrence 65 pamidronate 64 mCRC patients 64 nonmetastatic 64 surgical debulking 64 virological response 64 NSABP B 64 Platinol ® 64 nondiabetic patients 64 adjuvant radiation 64 CCyR 64 virologic failure 64 adriamycin 64 CHOP chemotherapy 64 paclitaxel eluting stents 64 adjuvant hormonal therapy 64 K ras mutations 64 alfa 2a 64 underwent surgical resection 64 progression TTP 64 decitabine 64 KRAS status 64 carboplatin paclitaxel 64 concurrent chemoradiation 64 chlorambucil 64 exemestane 64 sipuleucel T 64 mRCC 64 lenalidomide dexamethasone 64 Pemetrexed 64 FOLFOX4 64 NMIBC 64 symptomatic VTE 64 KRAS mutations occur 64 rFSH 64 iodixanol 64 CIMZIA TM 64 FOLFIRINOX 64 gemcitabine chemotherapy 64 pancreatic adenocarcinoma 64 HSCT 64 locoregional 64 metastatic renal cell carcinoma 64 EBRT 64 lymphadenectomy 64 endometrial carcinoma 64 sorafenib Nexavar 64 β blockers 64 8mg/kg 64 Exemestane 64 androgen ablation 64 prostate cancer CaP 64 CC genotype 64 gefitinib Iressa 63 Temsirolimus 63 RRMS patients 63 recurrent glioblastoma multiforme 63 plus dexamethasone 63 systemic ALCL 63 chemoembolization 63 liposomal amphotericin B 63 neoadjuvant therapy 63 Velcade bortezomib 63 hepatic metastases 63 neurologic progression 63 thalidomide dexamethasone 63 salmeterol fluticasone 63 methotrexate monotherapy 63 pelvic lymphadenectomy 63 hormone receptor negative 63 pomalidomide 63 gemcitabine Gemzar ® 63 tipranavir r 63 octreotide LAR 63 antiretroviral naïve 63 PEG IFN 63 topotecan 63 Fludara 63 dacarbazine 63 Degarelix 63 daunorubicin 63 peginterferon 63 ELACYT 63 viral kinetics 63 dosage regimens 63 daily subcutaneous injections 63 beta blocker therapy 63 5-fluorouracil/leucovorin 63 metastatic castration resistant 63 mycophenolate mofetil 63 leukemia AML 63 insulin detemir 63 epoetin alpha 63 Peg IFN 63 epirubicin 63 BEACOPP 63 Kaplan Meier analysis 63 everolimus eluting stents 63 fluvastatin 63 dose cytarabine 63 underwent liver transplantation 63 platelet inhibitor 63 virologic suppression 63 AROMASIN 63 metastatic hormone refractory 63 biologic DMARD 63 GnRH agonists 63 gemcitabine carboplatin 63 docetaxel prednisone 63 adjuvant chemotherapy 63 VELCADE melphalan 63 Natalizumab 63 achieved CCyR 63 warfarin therapy 63 Elitek 63 taxane therapy 63 HBeAg 63 rFVIIa 63 placebo dexamethasone 63 micafungin 63 folinic acid 63 paclitaxel carboplatin 63 APTIVUS 63 radiochemotherapy 62 cytoreductive surgery 62 nodal metastases 62 perioperatively 62 cisplatin chemotherapy 62 Combination therapy 62 dose dexamethasone 62 antiarrhythmic drugs 62 patients evaluable 62 Aptivus ® 62 Insulin detemir 62 SCIg 62 ritonavir boosted 62 alkylating agent 62 imatinib therapy 62 noninferior 62 stage IIIB 62 boosted protease inhibitor 62 CRp 62 postoperative radiotherapy 62 caspofungin 62 ErbB2 positive 62 Pegylated Interferon 62 EGFR mutation positive 62 mutated K ras 62 heavily pretreated 62 FOLFIRI 62 relapsed ovarian cancer 62 standard chemotherapy regimens 62 verteporfin 62 HBeAg negative 62 bortezomib Velcade 62 azacitidine 62 temozolomide TMZ 62 liver resection 62 PROSTVAC VF 62 radical prostatectomy RP 62 peritoneal carcinomatosis 62 antithymocyte globulin 62 CLL SLL 62 sustained virological response 62 fluoropyrimidine 62 Surgical resection 62 thalidomide Thalomid 62 5FU 62 Thal Dex 62 metastatic renal cell 62 phase IIb study 62 interferon alfa 62 aromatase inhibitors AIs 62 certolizumab 62 DMARD therapy 62 external beam radiotherapy 62 cytotoxic therapy 62 medically inoperable 62 ER CHOP 62 posttransplant 62 anti arrhythmic drug 62 prospectively defined 62 fluorouracil leucovorin 62 azacytidine 62 vandetanib 62 mcg BID 62 achieved sustained virological 62 FOLFOX6 62 cytogenetic responses 62 bendamustine 62 pT2 62 randomized multicenter trial 62 cisplatin gemcitabine 62 IFN α 62 oral Hycamtin 62 receptor blocker 62 HBeAg positive patients 62 ASCT 62 prostate carcinoma 62 androgen suppression therapy 62 chemotherapeutic regimens 62 Halaven 62 trabectedin 62 metastatic RCC 62 Platinol ® cisplatin 62 unresectable tumors 62 gemcitabine cisplatin 62 Irinotecan 62 Torisel 62 IFN beta 62 Neoadjuvant 62 refractory metastatic 62 F FDG PET 62 comparator arm 62 epoetin beta 62 CsA 62 castrate resistant 62 radical nephrectomy 62 sirolimus eluting stents 62 sunitinib 62 squamous histology 62 endocrine responsive 62 lymph node dissection 62 docetaxel Taxotere ® 62 FOLFOX 62 previously untreated follicular 62 NNRTI resistance 62 Ophena TM 62 posttreatment 62 EURIDIS 62 cisplatin vinorelbine 62 lumbar spine BMD 62 Vidaza azacitidine 62 Arimidex anastrozole 62 FOLPI 62 TACE 62 sentinel lymph node biopsy 62 paclitaxel Taxol ® 62 CYT# potent vascular disrupting 62 advanced hepatocellular carcinoma 62 virologic breakthrough 62 CIMZIA TM certolizumab pegol 62 abacavir Ziagen 62 HCV SPRINT 61 Folfox 61 nonmetastatic prostate cancer 61 Pegasys plus Copegus 61 zoledronate 61 CYPHER Stent 61 vidofludimus 61 lung metastases 61 perioperative morbidity 61 desvenlafaxine succinate 61 completely resected 61 HBeAg negative patients 61 abiraterone acetate 61 peg interferon 61 TAXUS Express Stent 61 nephrectomy 61 MabCampath 61 interferon therapy 61 alteplase 61 evaluating tivozanib 61 allogeneic transplant 61 coinfected patients 61 pain palliation 61 dose cohort 61 Platinol 61 allogeneic HSCT 61 darunavir ritonavir 61 mg kg dose 61 Retreatment 61 TMC# r 61 telaprevir dosed 61 thrombocytopenic 61 epithelial ovarian cancer 61 DAPT 61 cyclophosphamide methotrexate 61 morphometric vertebral fractures 61 melphalan prednisone 61 galiximab 61 fluorouracil 61 Fulvestrant 61 FOLFIRI alone 61 splenectomized patients 61 Lenalidomide 61 mg/m2 dose 61 radiotherapy RT 61 thromboprophylaxis 61 recurrent glioblastoma 61 KRAS wild 61 antiandrogen 61 cytoreductive nephrectomy 61 protease inhibitor PI 61 axillary node dissection 61 R# #mg BID 61 myeloablative 61 adalimumab Humira 61 metastatic malignant 61 paclitaxel Taxol R 61 pediatric acute lymphoblastic 61 resectable 61 R0 resection 61 cytogenetic abnormalities 61 AGILECT R 61 pegylated liposomal doxorubicin PLD 61 TORISEL 61 paclitaxel Taxol 61 metastatic kidney 61 trials RCTs 61 MAGE A3 ASCI 61 grade cervical intraepithelial 61 interferon ribavirin 61 locoregional disease 61 tipranavir ritonavir 61 LV dysfunction 61 saline placebo 61 IL#B 61 pyridostigmine 61 dacarbazine DTIC 61 Intravenous CP 61 xenograft models 61 androgen blockade 61 biochemical recurrence 61 q#h 61 imatinib Gleevec 61 taxane chemotherapy 61 idarubicin 61 hepatic resection 61 adjuvant endocrine therapy 61 cART 61 #mg/m# [002] 61 remission CR 61 weekly subcutaneous injections 61 cetuximab Erbitux 61 adefovir dipivoxil 61 nodal metastasis 61 unresectable stage 61 remission induction 61 pegylated interferon alpha 61 colorectal cancer liver metastases 61 cranial irradiation 61 inecalcitol 61 pharmacokinetic PK study 61 SLNB 61 metastatic bladder 61 paclitaxel cisplatin 61 oral allopurinol 61 methotrexate therapy 61 miglustat 61 HER2 positive metastatic breast 61 refractory AML 61 glatiramer acetate 61 ARB telmisartan 61 evaluable subjects 61 curative resection 61 divalproex sodium 61 efavirenz EFV 61 colorectal carcinoma 61 MCyR 61 IV NSCLC 61 oral diclofenac 61 TURBT 61 tumor resection 61 receptor tyrosine kinase inhibitor 61 HBeAg + 61 trastuzumab Herceptin ® 61 virologic response 61 KRAS mutations 61 ChronVac C R 61 paroxysmal AF 61 ritonavir boosted lopinavir 61 nab paclitaxel 61 BCG refractory 61 epirubicin cyclophosphamide 61 Hormone Refractory Prostate Cancer 61 tumor histology 61 recurrent metastatic 61 ZACTIMA 61 adjuvant therapies 61 BCIRG 61 VFEND 61 PSA nadir 61 Acute Coronary Syndromes ACS 61 metastatic malignant melanoma 61 PSADT 61 bevacizumab Avastin 61 Hycamtin ® 61 thromboembolic complications 61 dacarbazine chemotherapy 61 Erlotinib 61 Subgroup analysis 61 HER2 amplification 61 lanthanum carbonate 61 urothelial carcinoma 61 genotypic resistance 61 leukemia ALL 61 rimonabant #mg 61 HER2 negative 61 pyrazinamide 61 unfractionated heparin UFH 61 fallopian tube carcinoma 61 ribavirin therapy 61 GOUT 61 adalimumab 61 5 fluorouracil leucovorin 61 irbesartan 61 Amrubicin 61 sargramostim 61 peginterferon alfa 2a #KD 61 argatroban 61 demonstrated antitumor activity 60 metastatic gastric 60 immunomodulatory therapy 60 canakinumab 60 assessing T DM1 60 abacavir lamivudine 60 stage IIIB IV 60 NEVO ™ 60 PROSTVAC ® 60 letrozole Femara 60 dalteparin 60 oral anticoagulation 60 Radical prostatectomy 60 IFN alfa 60 Hodgkin lymphoma HL 60 recurrent myocardial infarction 60 PSMA ADC 60 angiographic outcomes 60 LHRH agonists 60 sulphonylureas 60 % CI #.#-#.# [003] 60 FUSILEV enhances 60 TP# mutations 60 capecitabine Xeloda 60 bladder carcinoma 60 olmesartan 60 evaluable 60 Telintra 60 NPH insulin 60 BRCA2 mutation carriers 60 hormone refractory 60 cancer mCRC 60 mitoxantrone plus 60 advanced adenoma 60 severe neutropenia 60 colorectal liver metastases 60 lipid lowering therapy 60 antibody titer 60 docetaxel 60 somatostatin analog 60 prostate adenocarcinoma 60 resected pancreatic cancer 60 childhood acute lymphoblastic 60 postmenopausal osteoporotic women 60 Taxotere ® 60 phase IIb trial 60 oral clodronate 60 Peginterferon alfa 2b 60 chemoresistant 60 SUTENT 60 conventional angiography 60 prostate cancer PCa 60 HoLEP 60 TTF Therapy 60 antioxidant supplementation 60 Bevacizumab Avastin 60 dosing cohort 60 tumor regressions 60 rHuEPO 60 CTAP# Capsules 60 exemestane Aromasin 60 FIRMAGON 60 Campath alemtuzumab 60 enzastaurin 60 cediranib 60 prior chemotherapy regimens 60 ALND 60 aromatase inhibitor AI 60 ACTEMRA TM 60 cyclophosphamide doxorubicin vincristine 60 Capecitabine 60 pemetrexed 60 LEXIVA r 60 visceral metastases 60 SPRYCEL ® 60 temsirolimus 60 Gliadel Wafer 60 tenofovir emtricitabine 60 relapsing multiple sclerosis 60 EOquin TM 60 ARIMIDEX 60 renal tumors 60 CIMZIA ™ 60 allogeneic transplantation 60 relapsed AML 60 anthracyclines taxanes 60 peginterferon alfa 60 contralateral breast 60 GnRH agonist 60 μmol L 60 amoxicillin clavulanate 60 Hazard Ratio 60 Stage IIIb 60 SCCHN 60 lymphocytosis 60 immunoconjugate 60 definite stent thrombosis 60 histological subtype 60 Gastrointestinal Stromal Tumors 60 Bezielle 60 refractory prostate cancer 60 Cimzia TM 60 Acute Myeloid Leukaemia AML 60 Decitabine 60 adjunctive placebo 60 cis retinoic acid 60 tenecteplase 60 de novo AML 60 TIMP 1 60 lapatinib Tykerb 60 levosimendan 60 briakinumab 60 adverse cytogenetics 60 riociguat 60 pretransplant 60 alpha 2a 60 Fludarabine 60 HER2 expression 60 EGFR TKI 60 PRADAXA #mg 60 GW# [003] 60 patients undergoing CABG 60 6 mercaptopurine 60 fludarabine cyclophosphamide 60 intravesical chemotherapy 60 metastatic CRC 60 KRAS mutant tumors 60 HER2 amplified 60 nadroparin 60 Vectibix monotherapy 60 prospectively stratified 60 fondaparinux 60 nephron sparing surgery 60 transarterial chemoembolization 60 #mg dosing group 60 immunosuppressive regimen 60 cinacalcet 60 anagrelide 60 satraplatin Phase 60 rhGH 60 prostate cancer CRPC 60 HBV vaccine 60 pegylated interferon alfa 2b 60 preoperative radiotherapy 60 BARACLUDE ® 60 4mg/kg 60 HNSCC 60 peginterferon alpha 2a 60 NSTE ACS 60 oxaliplatin Eloxatin 60 complete remissions 60 mitoxantrone chemotherapy 60 resminostat 60 cranial radiation 60 ALT normalization 60 postintervention 60 virologic responses 60 bolus dose 60 ara C 60 Afatinib 60 dose melphalan 60 HBeAg positive 60 colorectal carcinomas 60 ipsilateral stroke 60 hematological parameters 60 LHRH 60 intravenous bisphosphonates 60 sunitinib malate 60 refractory CLL 60 tolterodine 60 olaparib 60 CR CRu 60 ACZ# 60 median PFS 60 biliary tract cancer 60 docetaxel Taxotere 60 CLARITY study 60 Quinamed 60 oral deforolimus 60 follicular lymphomas 60 timepoints 60 cabazitaxel 60 serum calcium levels 60 hemodialysis patients 60 achieved ACR# 60 abnormal p# biomarker 60 potent antiretroviral therapy 59 Interferon alpha 59 APTIVUS R 59 care regimens CCR 59 therapeutic regimens 59 allogeneic SCT 59 dexamethasone Decadron 59 EGFR TKIs 59 elacytarabine 59 Myelodysplastic Syndrome MDS 59 hepatectomy 59 glycated hemoglobin levels 59 ibandronate 59 zotarolimus eluting stent 59 FluCAM 59 CYP#D# inhibitor 59 dimeglumine 59 lenalidomide Revlimid R 59 Allovectin 7 ® 59 non squamous NSCLC 59 FDG-PET/CT 59 axitinib 59 erlotinib Tarceva 59 anastrazole 59 Trastuzumab 59 liposomal doxorubicin 59 complete cytogenetic 59 ancrod 59 BEXXAR Therapeutic Regimen 59 colorectal adenoma 59 pegylated interferon alfa 2a 59 Tesmilifene 59 forodesine 59 neratinib 59 adjuvant trastuzumab 59 HCV genotype 59 liver metastases 59 Interferon alfa 59 prognostic markers 59 GPIIb IIIa inhibitors 59 q#d 59 Adefovir 59 ABCSG 59 pimecrolimus 59 idraparinux 59 Phase #/#a trial 59 bupropion SR 59 trastuzumab Herceptin R 59 response CCyR 59 null responder 59 HER2 positive cancers 59 nonfatal MI 59 pertuzumab 59 Nexavar sorafenib 59 CHAMPION PCI 59 reperfusion therapy 59 corticosteroid dexamethasone 59 gadobutrol 59 Peginterferon 59 Faslodex 59 VIDAZA 59 plus gemcitabine 59 chronic HCV 59 huN# DM1 59 PROLASTIN C 59 HORIZONS AMI trial 59 endocrine therapies 59 Azacitidine 59 nonsmall cell lung cancer 59 mapatumumab 59 sustained virologic response 59 Free Survival PFS 59 Nilotinib 59 Paraplatin ® 59 independent prognostic marker 59 lopinavir r 59 mycophenolate mofetil MMF 59 Leydig cell 59 irinotecan chemotherapy 59 renal cell carcinomas 59 mg kg cohorts 59 GAMMAGARD 59 interferon alfa 2a 59 mcg QD 59 prednisone prednisolone 59 PEGylated Fab fragment 59 STRIDE PD 59 intradermal injection 59 hepatitis C genotype 59 antibiotic regimens 59 recurrent NSCLC 59 Seliciclib 59 ß blockers 59 Dacogen decitabine 59 fluticasone salmeterol 59 Kaplan Meier estimate 59 prospectively randomized 59 paclitaxel poliglumex 59 interferon beta therapy 59 Cloretazine 59 RECORD1 59 paclitaxel chemotherapy 59 recurrent VTE 59 DOXIL 59 crizotinib PF # 59 endoscopic resection 59 TT genotype 59 TAXOTERE R 59 fulvestrant 59 acromegalic patients 59 distant metastases 59 antidepressant therapy 59 hepatocellular cancer 59 relapsing remitting MS RRMS 59 infusional 5-FU/LV 59 malignant pleural mesothelioma 59 Phase IIIb clinical 59 Xanafide 59 seropositive patients 59 invasive carcinomas 59 glycosylated hemoglobin levels 59 azathioprine 59 MADIT II 59 dasatinib Sprycel 59 AGILECT ® 59 Jevtana 59 COPAXONE ® 59 randomized multicenter Phase III 59 tipranavir 59 taxane refractory 59 histologically proven 59 trastuzumab Herceptin 59 NATRECOR ® 59 pT3 59 hA# 59 pulmonary metastases 59 sevelamer 59 TMP SMX 59 antibody MAb 59 oral rivaroxaban 59 RhuDex R 59 atorvastatin #mg 59 intradermal injections 59 Revlimid lenalidomide 59 cisplatin resistant 59 autologous transplants 59 TPV r 59 cisplatin 59 univariate analysis 59 HER2 positive tumors 59 elotuzumab 59 hepatocellular carcinomas 59 RE LY trial 59 Pegasys peginterferon alfa 2a 59 cytotoxic chemotherapy 59 subcutaneous SC 59 trastuzumab 59 strontium ranelate 59 hormone therapy estrogen 59 SSc 59 operable pancreatic cancer 59 Randomized Evaluation 59 SVR# 59 intravenous cyclophosphamide 59 HER2 overexpression 59 carboplatin chemotherapy 59 receiving highly emetogenic 59 mg/m2 IV 59 IRESSA 59 PASI scores 59 retransplantation 59 durable remissions 59 baseline LDH 59 lamivudine refractory patients 59 adrenalectomy 59 dasatinib 59 glycoprotein IIb IIIa inhibitors 59 mcg albinterferon alfa 2b 59 landmark ATHENA trial 59 nodular partial response 59 OvaRex MAb 59 5 Fluorouracil 59 trans retinoic acid 59 carotid endarterectomy CEA 59 gemcitabine 59 chemoprevention trials 59 allogeneic stem cell 59 Allogeneic 59 lupus anticoagulant 59 BRAF V#E mutation 59 adenoma recurrence 59 Mitoxantrone 59 progestin therapy 59 salpingo oophorectomy 59 Mylotarg 59 prostate cancer HRPC 59 mucosal healing 59 comparator PI r 59 FOLFOX4 alone 59 Hydroxyurea 59 AVODART 59 null responder HCV 59 clopidogrel Plavix 59 generation purine nucleoside 59 rituximab Rituxan 59 cyclophosphamide chemotherapy 59 underwent radical cystectomy 59 low dose dexamethasone 59 Prognostic factors 59 fibrinolysis 59 cystectomy 59 aldosterone antagonists 59 Aromasin 59 bleomycin 59 anti angiogenic agents 59 ovarian carcinoma 59 Adjuvant therapy 59 inhibitor RG# 59 androgen independent 59 rtPA 59 recurrent venous thromboembolism 59 #mg BID [003] 59 VNP#M 59 mCRPC 59 selective modulator 59 tumor necrosis 59 untreated AML 59 concomitant medications 59 oncologic outcomes 59 sorafenib Nexavar ® 59 undergone radical prostatectomy 59 PCa 59 tolterodine ER 59 eribulin 59 relapsed CLL 59 CALGB # [002] 59 GVAX 59 vinorelbine 59 preterm newborns 59 recurrent malignant glioma 58 tumor xenograft models 58 refractory chronic lymphocytic 58 rituximab monotherapy 58 antiestrogen therapy 58 teriflunomide 58 hormone refractory metastatic prostate 58 intratympanic 58 gadolinium enhanced 58 tamoxifen 58 de novo kidney transplant 58 radical cystectomy 58 Phase III randomized controlled 58 reinfarction 58 relapsed ALL 58 subanalysis 58 urothelial bladder cancer 58 BENICAR HCT 58 intratumoral 58 sleeve lobectomy 58 estrogen progestin therapy 58 TKI therapy 58 histologic subtype 58 antidiabetic therapy 58 Accelerated Partial Breast Irradiation 58 CALGB 58 mg QD 58 resistant hormone refractory 58 CIMZIA R 58 haematologic 58 luteinizing hormone releasing 58 basal cell carcinoma BCC 58 randomized Phase 2b 58 prognostic indicators 58 hemorrhagic complications 58 DOXIL ® 58 eplerenone 58 PROLARIS 58 #mg/day [002] 58 lispro 58 bicalutamide 58 T2DM 58 etoposide 58 Virologic 58 myelodysplastic myeloproliferative diseases 58 seliciclib 58 tamsulosin 58 colesevelam HCl 58 d4T stavudine Zerit 58 pancreatic neuroendocrine tumors 58 chronic hemodialysis 58 neoadjuvant radiation 58 p#HER# positive 58 T1c 58 TRAIL R1 58 Renal Cell Carcinoma RCC 58 tamoxifen Nolvadex ® 58 Randomized trials 58 RoACTEMRA 58 peg IFN 58 multicenter randomized controlled 58 Gleevec imatinib 58 intravitreal injections 58 mg/m2 cohort 58 IM progesterone 58 Adjuvant Treatment 58 anthracycline containing 58 LEUKINE 58 papillary renal cell carcinoma 58 advanced adenomas 58 Pegylated Liposomal Doxorubicin 58 macroalbuminuria 58 Partial Responses 58 avosentan 58 Allovectin 7 58 CANCIDAS 58 uridine triacetate 58 parathyroidectomy 58 radioiodine therapy 58 mcg dose 58 endoscopic remission 58 DCVax ® Brain 58 oral ridaforolimus 58 liposomal formulation 58 MVax 58 HCV infected 58 Patients Receiving 58 phase IIb clinical 58 intact parathyroid hormone 58 antiandrogens 58 haematologic malignancies 58 RSR# efaproxiral 58 HPV-#/# 58 skeletal metastases 58 multivariate analyzes 58 evaluable patients 58 Atypical Hemolytic Uremic Syndrome 58 ixabepilone